A Phase 1 interventional study of TAK-438ASA and TAK-438 in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in Japan. Open to male participants aged 20 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-19.
Sponsored by Takeda · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purposes of this study are to evaluate BE between a single-dose of TAK-438ASA tablet versus a single-dose combination of TAK-438 tablet 10 milligram (mg) and aspirin enteric-coated tablet 100 mg in Japanese healthy adult men (Study 1), and to evaluate the effects of food on the pharmacokinetics of TAK-438ASA tablet in Japanese healthy adult men (Study 2).
The drug under investigation in this study is called TAK-438ASA. TAK-438ASA is being tested in Japanese healthy adult men. This study consists of two studies to evaluate bioequivalence (Study 1) and the effects of food (Study 2). Study 1 (split into a Pilot phase and a Pivotal phase) will look at bioequivalence between a single-dose of TAK-438ASA tablet versus a single-dose combination of TAK-438 tablet 10 mg and aspirin enteric-coated tablet 100 mg. Study 2 will look at the effects of food on the pharmacokinetics of TAK-438ASA tablet.
The study will enroll up to 440 participants in total (Study 1 + 2). For Study 1, 12 participants per group (24 participants in total) will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups for the pilot study to estimate the sample size of Pivotal study. After pilot study, 202 participants as a maximum per group (404 participants in total) will be randomly assigned to one of the two treatment groups:
For Study 2, 6 participants per group (12 participants in total) will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in the Pilot phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 2 in the Pilot phase of Study 1 (Day 16).
Drug: TAK-438ASA · Drug: TAK-438 · Drug: Aspirin
One TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 1 in the Pilot phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by, one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in the Pilot phase of Study 1 (Day 16).
Drug: TAK-438ASA · Drug: TAK-438 · Drug: Aspirin
One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in the Pivotal phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 2 in the Pivotal phase of Study 1 (Day 16).
Drug: TAK-438ASA · Drug: TAK-438 · Drug: Aspirin
One TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 1 in the Pivotal phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in the Pivotal phase of Study 1 (Day 16).
Drug: TAK-438ASA · Drug: TAK-438 · Drug: Aspirin
One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in Study 2 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally 30 minutes after breakfast, on Day 1 of Period 2 in Study 2 (Day 16).
Drug: TAK-438ASA
One TAK-438ASA tablet, orally 30 minutes after breakfast, on Day 1 of Period 1 in Study 2 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in Study 2 (Day 16).
Drug: TAK-438ASA
Study 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Free Base of TAK-438 (TAK-438F)
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Study 1, Cmax: Maximum Observed Plasma Concentration for TAK-438F
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Study 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Unchanged Aspirin
Time frame: Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose
Study 1, Cmax: Maximum Observed Plasma Concentration for Unchanged Aspirin
Time frame: Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose
Study 1, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Study 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Study 1, MRT (Infinity,ev): Mean Residence Time From Time 0 to Infinity for TAK-438F
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Study 1, Lambda (z): Terminal Disposition Phase Rate Constant for TAK-438F
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Study 1, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Unchanged Aspirin
Time frame: Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose
Study 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Unchanged Aspirin
Time frame: Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose
Study 1, MRT (Infinity,ev): Mean Residence Time From Time 0 to Infinity for Unchanged Aspirin
Time frame: Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose
Study 1, Lambda (z): Terminal Disposition Phase Rate Constant for Unchanged Aspirin
Time frame: Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose
Study 2, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F and Its Metabolites (M) (M-I, M-II, M-III and M-IV-Sul)
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Study 2, AUC(0-48): Area Under the Plasma Concentration-time Curve From Time 0 to Time 48 Hours Over the Dosing Interval for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Study 2, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Study 2, Cmax: Maximum Observed Plasma Concentration for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Study 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Study 2, T1/2z: Terminal Disposition Phase Half-life for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Study 2, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Unchanged Aspirin and Its Metabolite (Salicylic Acid)
Time frame: Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose
Study 2, AUC(0-24): Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours Over the Dosing Interval for Unchanged Aspirin and Its Metabolite (Salicylic Acid)
Time frame: Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose
Study 2, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Unchanged Aspirin and Its Metabolite (Salicylic Acid)
Time frame: Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose
Study 2, Cmax: Maximum Observed Plasma Concentration for Unchanged Aspirin and Its Metabolite (Salicylic Acid)
Time frame: Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose
Study 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Unchanged Aspirin and Its Metabolite (Salicylic Acid)
Time frame: Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose
Study 2, T1/2z: Terminal Disposition Phase Half-life for Unchanged Aspirin and Its Metabolite (Salicylic Acid)
Time frame: Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose
Study 2, Ae(0-48): Amount of Drug Excreted in Urine From Time 0 to 48 Hours for TAK-438F and Its Metabolites (M-I, M-II, M-III, and M-IV-Sul)
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Study 2, Fe(0-48): Fraction of Administered Dose Excreted Into Urine From Time 0 to Time 48 Hours for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Study 2, CLR: Renal Clearance for TAK-438F and Its Metabolites (M-I, M-II, M-III, and M-IV-Sul)
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Study 2, Ae(0-24): Amount of Drug Excreted in Urine From Time 0 to 24 Hours for Unchanged Aspirin and Its Metabolites (Salicylic Acid and Salicyluric Acid)
Time frame: Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose
Study 2, Fe(0-24): Fraction of Administered Dose Excreted Into Urine From Time 0 to Time 24 Hours for Unchanged Aspirin and Its Metabolites (Salicylic Acid and Salicyluric Acid)
Time frame: Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose
Study 2, CLR: Renal Clearance for Unchanged Aspirin and Its Metabolites (Salicylic Acid and Salicyluric Acid)
Time frame: Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose
Participants took part in the study at 1 investigative site in Japan from 8 March 2018 to 12 October 2018.
| Milestone | Pilot Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin | Pilot Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA | Pivotal Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin | Pivotal Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA | Study 2, Sequence C: TAK-438ASA (Fasted + Fed Condition) | Study 2, Sequence D: TAK-438ASA (Fed + Fasted Condition) |
|---|---|---|---|---|---|---|
| Started | 12 | 12 | 120 | 120 | 6 | 6 |
| Completed | 12 | 12 | 120 | 120 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Pilot Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin | Pilot Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA | Pivotal Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin | Pivotal Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA | Study 2, Sequence C: TAK-438ASA (Fasted + Fed Condition) | Study 2, Sequence D: TAK-438ASA (Fed + Fasted Condition) |
|---|---|---|---|---|---|---|
| Started | 12 | 12 | 120 | 120 | 6 | 6 |
| Completed | 12 | 12 | 119 | 118 | 6 | 6 |
| Not completed | 0 | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 2 | 0 | 0 |
| Milestone | Pilot Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin | Pilot Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA | Pivotal Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin | Pivotal Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA | Study 2, Sequence C: TAK-438ASA (Fasted + Fed Condition) | Study 2, Sequence D: TAK-438ASA (Fed + Fasted Condition) |
|---|---|---|---|---|---|---|
| Started | 12 | 12 | 119 | 118 | 6 | 6 |
| Completed | 11 | 12 | 119 | 117 | 6 | 6 |
| Not completed | 1 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 1 | 0 | 0 |
| hour*nanogram per milliliter (h*ng/mL) | Pilot Study 1: TAK-438ASA | Pilot Study 1: TAK-438 and Aspirin | Pivotal Study 1: TAK-438ASA | Pivotal Study 1: TAK-438 and Aspirin |
|---|---|---|---|---|
| Study 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Free Base of TAK-438 (TAK-438F) | 92.46 ± 32.128 | 91.95 ± 31.431 | — | — |
| nanogram per milliliter (ng/mL) | Pilot Study 1: TAK-438ASA | Pilot Study 1: TAK-438 and Aspirin | Pivotal Study 1: TAK-438ASA | Pivotal Study 1: TAK-438 and Aspirin |
|---|---|---|---|---|
| Study 1, Cmax: Maximum Observed Plasma Concentration for TAK-438F | 13.87 ± 5.0945 | 13.22 ± 5.0778 | — | — |
| h*ng/mL | Pilot Study 1: TAK-438ASA | Pilot Study 1: TAK-438 and Aspirin | Pivotal Study 1: TAK-438ASA | Pivotal Study 1: TAK-438 and Aspirin |
|---|---|---|---|---|
| Study 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Unchanged Aspirin | 873.5 ± 220.94 | 831.9 ± 350.69 | 912.3 ± 327.58 | 832.7 ± 323.46 |
| ng/mL | Pilot Study 1: TAK-438ASA | Pilot Study 1: TAK-438 and Aspirin | Pivotal Study 1: TAK-438ASA | Pivotal Study 1: TAK-438 and Aspirin |
|---|---|---|---|---|
| Study 1, Cmax: Maximum Observed Plasma Concentration for Unchanged Aspirin | 647.6 ± 326.77 | 597.5 ± 507.90 | 701.8 ± 349.18 | 558.0 ± 404.26 |
| h*ng/mL | Pilot Study 1: TAK-438ASA | Pilot Study 1: TAK-438 and Aspirin | Pivotal Study 1: TAK-438ASA | Pivotal Study 1: TAK-438 and Aspirin |
|---|---|---|---|---|
| Study 1, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F | 94.71 ± 32.334 | 93.78 ± 31.828 | — | — |
| hour | Pilot Study 1: TAK-438ASA | Pilot Study 1: TAK-438 and Aspirin | Pivotal Study 1: TAK-438ASA | Pivotal Study 1: TAK-438 and Aspirin |
|---|---|---|---|---|
| Study 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F | 1.500 (1.00 to 3.00) | 1.500 (1.00 to 3.00) | — | — |
| hour | Pilot Study 1: TAK-438ASA | Pilot Study 1: TAK-438 and Aspirin | Pivotal Study 1: TAK-438ASA | Pivotal Study 1: TAK-438 and Aspirin |
|---|---|---|---|---|
| Study 1, MRT (Infinity,ev): Mean Residence Time From Time 0 to Infinity for TAK-438F | 9.610 ± 1.2440 | 9.751 ± 1.3853 | — | — |
| 1 per hour | Pilot Study 1: TAK-438ASA | Pilot Study 1: TAK-438 and Aspirin | Pivotal Study 1: TAK-438ASA | Pivotal Study 1: TAK-438 and Aspirin |
|---|---|---|---|---|
| Study 1, Lambda (z): Terminal Disposition Phase Rate Constant for TAK-438F | 0.08565 ± 0.0090230 | 0.08788 ± 0.013025 | — | — |
| h*ng/mL | Pilot Study 1: TAK-438ASA | Pilot Study 1: TAK-438 and Aspirin | Pivotal Study 1: TAK-438ASA | Pivotal Study 1: TAK-438 and Aspirin |
|---|---|---|---|---|
| Study 1, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Unchanged Aspirin | 876.5 ± 221.10 | 834.6 ± 349.28 | 915.8 ± 328.82 | 855.4 ± 322.27 |
| hour | Pilot Study 1: TAK-438ASA | Pilot Study 1: TAK-438 and Aspirin | Pivotal Study 1: TAK-438ASA | Pivotal Study 1: TAK-438 and Aspirin |
|---|---|---|---|---|
| Study 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Unchanged Aspirin | 4.000 (2.50 to 8.50) | 4.500 (3.00 to 8.50) | 4.000 (2.00 to 11.0) | 4.500 (1.00 to 12.0) |
| hour | Pilot Study 1: TAK-438ASA | Pilot Study 1: TAK-438 and Aspirin | Pivotal Study 1: TAK-438ASA | Pivotal Study 1: TAK-438 and Aspirin |
|---|---|---|---|---|
| Study 1, MRT (Infinity,ev): Mean Residence Time From Time 0 to Infinity for Unchanged Aspirin | 4.629 ± 1.4634 | 5.194 ± 1.5154 | 4.398 ± 1.0552 | 5.152 ± 2.0334 |
| 1 per hour | Pilot Study 1: TAK-438ASA | Pilot Study 1: TAK-438 and Aspirin | Pivotal Study 1: TAK-438ASA | Pivotal Study 1: TAK-438 and Aspirin |
|---|---|---|---|---|
| Study 1, Lambda (z): Terminal Disposition Phase Rate Constant for Unchanged Aspirin | 1.734 ± 0.30398 | 1.703 ± 0.30765 | 1.754 ± 0.32224 | 1.795 ± 0.35228 |
| h*ng/mL | Study 2: TAK-438ASA Fasted | Study 2: TAK-430ASA Fed |
|---|---|---|
| TAK-438F | 84.26 ± 16.890 | 104.3 ± 19.470 |
| M-I | 290.4 ± 50.706 | 266.9 ± 44.125 |
| M-II | 50.77 ± 19.175 | 58.29 ± 63.088 |
| M-III | 83.59 ± 15.202 | 80.25 ± 22.318 |
| M-IV-Sul | 115.9 ± 37.933 | 97.60 ± 40.882 |
| h*ng/mL | Study 2: TAK-438ASA Fasted | Study 2: TAK-430ASA Fed |
|---|---|---|
| TAK-438F | 82.89 ± 16.467 | 102.9 ± 18.851 |
| M-I | 272.1 ± 49.341 | 251.9 ± 44.461 |
| M-II | 30.80 ± 14.808 | 24.17 ± 12.927 |
| M-III | 82.96 ± 14.931 | 79.69 ± 22.117 |
| M-IV-Sul | 111.5 ± 38.376 | 93.20 ± 41.338 |
| h*ng/mL | Study 2: TAK-438ASA Fasted | Study 2: TAK-438ASA Fed |
|---|---|---|
| TAK-438F | 82.23 ± 16.775 | 102.4 ± 19.138 |
| M-I | 258.6 ± 49.384 | 239.5 ± 44.950 |
| M-II | 26.86 ± 12.921 | 20.66 ± 10.882 |
| M-III | 81.92 ± 15.032 | 78.69 ± 21.959 |
| M-IV-Sul | 108.4 ± 36.884 | 89.48 ± 39.843 |
| ng/mL | Study 2: TAK-438ASA Fasted | Study 2: TAK-438ASA Fed |
|---|---|---|
| TAK-438F | 12.73 ± 2.5465 | 18.35 ± 5.4137 |
| M-I | 41.26 ± 9.0261 | 35.22 ± 9.6886 |
| M-II | 2.820 ± 0.83815 | 2.131 ± 0.57491 |
| M-III | 15.38 ± 2.7078 | 14.90 ± 2.2273 |
| M-IV-Sul | 28.52 ± 7.8634 | 23.09 ± 7.4466 |
| hour | Study 2: TAK-438ASA Fasted | Study 2: TAK-438ASA Fed |
|---|---|---|
| TAK-438F | 1.500 (1.00 to 2.00) | 1.500 (1.00 to 3.00) |
| M-I | 1.500 (1.00 to 1.50) | 1.500 (1.00 to 4.00) |
| M-II | 4.000 (3.00 to 4.00) | 4.000 (4.00 to 10.0) |
| M-III | 1.750 (1.00 to 2.00) | 2.000 (1.00 to 4.00) |
| M-IV-Sul | 1.500 (1.00 to 3.00) | 2.000 (1.50 to 4.00) |
| hour | Study 2: TAK-438ASA Fasted | Study 2: TAK-438ASA Fed |
|---|---|---|
| TAK-438F | 8.293 ± 1.1254 | 7.951 ± 0.82489 |
| M-I | 9.653 ± 1.3591 | 9.153 ± 1.0688 |
| M-II | 12.92 ± 10.029 | 27.52 ± 38.721 |
| M-III | 6.797 ± 2.1059 | 6.826 ± 1.5924 |
| M-IV-Sul | 4.067 ± 1.4194 | 4.543 ± 1.6209 |
| h*ng/mL | Study 2: TAK-438ASA Fasted | Study 2: TAK-438ASA Fed |
|---|---|---|
| Unchanged aspirin | 817.9 ± 296.13 | 1008 ± 221.75 |
| Salicylic acid | 20010 ± 5299.3 | 20290 ± 5048.4 |
| h*ng/mL | Study 2: TAK-438ASA Fasted | Study 2: TAK-438ASA Fed |
|---|---|---|
| Unchanged aspirin | 816.7 ± 295.55 | 1007 ± 222.08 |
| Salicylic acid | 20070 ± 5318.8 | 20340 ± 5119.5 |
| h*ng/mL | Study 2: TAK-438ASA Fasted | Study 2: TAK-438ASA Fed |
|---|---|---|
| Unchanged aspirin | 816.5 ± 295.68 | 1007 ± 222.45 |
| Salicylic acid | 19370 ± 5108.5 | 19760 ± 4853.5 |
| ng/mL | Study 2: TAK-438ASA Fasted | Study 2: TAK-438ASA Fed |
|---|---|---|
| Unchanged aspirin | 632.5 ± 286.18 | 949.0 ± 415.75 |
| Salicylic acid | 4414 ± 930.76 | 5374 ± 1119.4 |
| hour | Study 2: TAK-438ASA Fasted | Study 2: TAK-438ASA Fed |
|---|---|---|
| Unchanged aspirin | 4.500 (2.00 to 6.00) | 4.000 (2.50 to 7.00) |
| Salicylic acid | 5.500 (3.50 to 6.50) | 4.500 (3.00 to 8.00) |
| hour | Study 2: TAK-438ASA Fasted | Study 2: TAK-438ASA Fed |
|---|---|---|
| Unchanged aspirin | 0.3749 ± 0.042784 | 0.4373 ± 0.10311 |
| Salicylic acid | 2.050 ± 0.32982 | 1.901 ± 0.26555 |
| microgram (mcg) | Study 2: TAK-438ASA Fasted | Study 2: TAK-438ASA Fed |
|---|---|---|
| TAK-438F | 433.3 ± 63.305 | 583.1 ± 110.83 |
| M-I | 150.1 ± 99.765 | 153.4 ± 61.628 |
| M-II | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| M-III | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| M-IV-Sul | 237.0 ± 56.783 | 196.8 ± 59.876 |
| percentage of dose | Study 2: TAK-438ASA Fasted | Study 2: TAK-438ASA Fed |
|---|---|---|
| TAK-438F | 4.333 ± 0.63305 | 5.831 ± 1.1083 |
| M-I | 1.499 ± 0.99551 | 1.529 ± 0.61494 |
| M-II | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| M-III | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| M-IV-Sul | 1.854 ± 0.44353 | 1.539 ± 0.46709 |
| liter per hour (l/h) | Study 2: TAK-438ASA Fasted | Study 2: TAK-438ASA Fed |
|---|---|---|
| TAK-438F | 5.213 ± 0.65760 | 5.604 ± 0.55389 |
| M-I | 0.5577 ± 0.38695 | 0.6018 ± 0.21705 |
| M-II | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| M-III | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| M-IV-Sul | 2.148 ± 0.59016 | 2.126 ± 0.66434 |
| mcg | Study 2: TAK-438ASA Fasted | Study 2: TAK-438ASA Fed |
|---|---|---|
| Unchanged aspirin | 481.3 ± 173.04 | 817.3 ± 403.78 |
| Salicylic acid | 2318 ± 1904.7 | 2076 ± 1159.4 |
| Salicyluric acid | 80180 ± 9852.2 | 83800 ± 4019.7 |
| percentage of dose | Study 2: TAK-438ASA Fasted | Study 2: TAK-438ASA Fed |
|---|---|---|
| Unchanged aspirin | 0.4813 ± 0.17304 | 0.8173 ± 0.40378 |
| Salicylic acid | 3.025 ± 2.4834 | 2.708 ± 1.5127 |
| Salicyluric acid | 74.02 ± 9.0984 | 77.34 ± 3.7218 |
| l/h | Study 2: TAK-438ASA Fasted | Study 2: TAK-438ASA Fed |
|---|---|---|
| Unchanged aspirin | 0.6181 ± 0.28917 | 0.7818 ± 0.29682 |
| Salicylic acid | 0.1135 ± 0.083534 | 0.1022 ± 0.055826 |
Collected over Treatment-emergent adverse events are adverse events (AE) that started after the first dose of study drug and no more than 2 days after the last dose of study drug in Period 2 (Day 18). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pilot Study 1: TAK-438ASA | 0/24 (0%) | 0/24 (0%) | 1/24 (4.2%) |
| Pilot Study 1: TAK-438 and Aspirin | 0/23 (0%) | 0/23 (0%) | 0/23 (0%) |
| Pivotal Study 1: TAK-438ASA | 0/237 (0%) | 0/237 (0%) | 8/237 (3.4%) |
| Pivotal Study 1: TAK-438 and Aspirin | 0/239 (0%) | 0/239 (0%) | 3/239 (1.3%) |
| Study 2: TAK-438ASA Fasted | 0/12 (0%) | 0/12 (0%) | 1/12 (8.3%) |
| Study 2: TAK-438ASA Fed | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) |
| Event | Pilot Study 1: TAK-438ASA | Pilot Study 1: TAK-438 and Aspirin | Pivotal Study 1: TAK-438ASA | Pivotal Study 1: TAK-438 and Aspirin | Study 2: TAK-438ASA Fasted | Study 2: TAK-438ASA Fed |
|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 1/24 | 0/23 | 0/237 | 0/239 | 1/12 | 0/12 |
| PharyngitisInfections and infestations | 0/24 | 0/23 | 6/237 | 2/239 | 0/12 | 0/12 |
| NasopharyngitisInfections and infestations | 0/24 | 0/23 | 2/237 | 0/239 | 0/12 | 0/12 |
| Liver function test abnormalInvestigations | 0/24 | 0/23 | 0/237 | 1/239 | 0/12 | 0/12 |
The safety analysis set was defined as all participants who received at least one dose of study drug.
| Age, Customized(Participants) | Pilot Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin | Pilot Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA | Pivotal Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin | Pivotal Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA | Study 2, Sequence C: TAK-438ASA (Fasted + Fed Condition) | Study 2, Sequence D: TAK-438ASA (Fed + Fasted Condition) | Total |
|---|---|---|---|---|---|---|---|
| Less than (<) 20 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 20 and 60 years | 12 | 12 | 120 | 120 | 6 | 6 | 276 |
| Greater than (>) 60 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Pilot Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin | Pilot Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA | Pivotal Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin | Pivotal Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA | Study 2, Sequence C: TAK-438ASA (Fasted + Fed Condition) | Study 2, Sequence D: TAK-438ASA (Fed + Fasted Condition) | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 12 | 12 | 120 | 120 | 6 | 6 | 276 |
| Race and Ethnicity Not Collected(Participants) | Pilot Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin | Pilot Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA | Pivotal Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin | Pivotal Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA | Study 2, Sequence C: TAK-438ASA (Fasted + Fed Condition) | Study 2, Sequence D: TAK-438ASA (Fed + Fasted Condition) | Total |
|---|---|---|---|---|---|---|---|
| Count of participants | — | — | — | — | — | — | 0 |
| Region of Enrollment(Participants) | Pilot Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin | Pilot Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA | Pivotal Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin | Pivotal Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA | Study 2, Sequence C: TAK-438ASA (Fasted + Fed Condition) | Study 2, Sequence D: TAK-438ASA (Fed + Fasted Condition) | Total |
|---|---|---|---|---|---|---|---|
| Japan | 12 | 12 | 120 | 120 | 6 | 6 | 276 |
| Consumption of caffeine(Participants) | Pilot Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin | Pilot Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA | Pivotal Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin | Pivotal Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA | Study 2, Sequence C: TAK-438ASA (Fasted + Fed Condition) | Study 2, Sequence D: TAK-438ASA (Fed + Fasted Condition) | Total |
|---|---|---|---|---|---|---|---|
| Had caffeine consumption | 6 | 5 | 23 | 18 | 2 | 1 | 55 |
| Had no caffeine consumption | 6 | 7 | 97 | 102 | 4 | 5 | 221 |
| Consumption of alcohol(Participants) | Pilot Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin | Pilot Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA | Pivotal Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin | Pivotal Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA | Study 2, Sequence C: TAK-438ASA (Fasted + Fed Condition) | Study 2, Sequence D: TAK-438ASA (Fed + Fasted Condition) | Total |
|---|---|---|---|---|---|---|---|
| Drank daily | 2 | 0 | 1 | 3 | 0 | 0 | 6 |
| Drank a few times per week | 2 | 2 | 9 | 9 | 0 | 0 | 22 |
| Drank a few times per month | 3 | 5 | 72 | 68 | 3 | 3 | 154 |
| Never drank | 5 | 5 | 38 | 40 | 3 | 3 | 94 |
| Smoking classification(Participants) | Pilot Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin | Pilot Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA | Pivotal Study 1, Sequence A: TAK-438ASA + TAK-438 and Aspirin | Pivotal Study 1, Sequence B: TAK-438 and Aspirin + TAK-438ASA | Study 2, Sequence C: TAK-438ASA (Fasted + Fed Condition) | Study 2, Sequence D: TAK-438ASA (Fed + Fasted Condition) | Total |
|---|---|---|---|---|---|---|---|
| Never smoked | 7 | 6 | 81 | 76 | 4 | 4 | 178 |
| Current smoker | 2 | 0 | 9 | 12 | 1 | 1 | 25 |
| Ex-smoker | 3 | 6 | 30 | 32 | 1 | 1 | 73 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Mar 2018 to primary completion in Oct 2018, 7 months.
Results were first posted in Nov 2019, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.